Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities

Oncologist

Volumn 19, Issue 8, 2014, Pages 805-813

  Dieci, Maria Vittoria ^a,b   Orvieto, Enrico ^c   Dominici, Massimo ^d   Conte, PierFranco ^a,b   Guarneri, Valentina ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Cribriform carcinoma; Medullary carcinoma; Metaplastic carcinoma; Mucinous carcinoma; Pleomorphic lobular cancer; Tubular carcinoma

Indexed keywords

BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; KI 67 ANTIGEN; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; TUMOR MARKER;

ADENOID CYSTIC CARCINOMA; APOCRINE CARCINOMA; BREAST CANCER; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; COLLOID CARCINOMA; GENE EXPRESSION PROFILING; GENE MUTATION; HIGH GRADE SMALL CELL NEUROENDOCRINE CARCINOMA; HORMONE RECEPTOR NEGATIVE BREAST CANCER; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CRIBRIFORM CARCINOMA; INVASIVE MICROPAPILLARY CARCINOMA; MEDULLARY CARCINOMA; PLEOMORPHIC LOBULAR CARCINOMA; PRIORITY JOURNAL; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUBULAR CARCINOMA; ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; BIOSYNTHESIS; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; CLASSIFICATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; RARE DISEASE;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; RARE DISEASES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84905483842     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0108     Document Type: Review

References (87)

1. Tavassoli FA, Devilee P. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon, France: IARC Press, 2003.
2. Lakhani SR, Ellis IO, Schnitt SJ et al. WHO Classification of Tumors of the Breast. Lyon, France: IARC, 2012.
3. Northridge ME, Rhoads GG, Wartenberg D et al. The importance of histologic type on breast cancer survival. J Clin Epidemiol 1997; 50: 283-290.
4. Rakha EA, Lee AH, Evans AJ et al. Tubular carcinoma of the breast: Further evidence to support its excellent prognosis. J Clin Oncol 2010; 28: 99-104.
5. Luini A, Aguilar M, Gatti G et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: The experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 2007; 101: 349-353.
6. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
7. Prat A, Parker JS, Karginova O et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
8. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
9. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223.
10. Curtis C, Shah SP, Chin SF et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
11. Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216: 141-150.
12. Horlings HM, Weigelt B, Anderson EM et al. Genomic profiling of histological special types of breast cancer. Breast Cancer Res Treat 2013; 142: 257-269.
13. Capella C, Eusebi V, Mann B et al. Endocrine differentiation in mucoid carcinoma of the breast. Histopathology 1980; 4: 613-630.
14. Clayton F. Pure mucinous carcinomas of breast: Morphologic features and prognostic correlates. Hum Pathol 1986; 17: 34-38.
15. Silverberg SG, Kay S, Chitale AR et al. Colloid carcinoma of the breast. Am J Clin Pathol 1971; 55: 355-363.
16. Tan PH, Tse GMK, Bay BH. Mucinous breast lesions: Diagnostic challenges. J Clin Pathol 2008; 61: 11-19.
17. Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11, 400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 2008; 111: 541-547.
18. Norris HJ, Taylor HB. Prognosis of mucinous (gelatinous) carcinoma of the breast. Cancer 1965; 18: 879-885.
19. Memis A, Ozdemir N, Parildar M et al. Mucinous (colloid) breast cancer: Mammographic and US features with histologic correlation. Eur J Radiol 2000; 35: 39-43.
20. Diab SG, Clark GM, Osborne CK et al. Tumor characteristics and clinical outcome of tubular and mucinousbreast carcinomas. J Clin Oncol 1999; 17: 1442-1448.
21. Günhan-Bilgen I, Oktay A. Tubular carcinomaof the breast: Mammographic, sonographic, clinical and pathologic findings. Eur J Radiol 2007; 61: 158-162.
22. Oakley GJ 3rd, Tubbs RR, Crowe J et al. HER-2 amplification in tubular carcinoma of the breast. Am J Clin Pathol 2006; 126: 55-58.
23. Louwman MW, Vriezen M, van Beek MW et al. Uncommon breast tumors in perspective: Incidence, treatment and survival in the Netherlands. Int J Cancer 2007; 121: 127-135.
24. Stutz JA, Evans AJ, Pinder S et al. The radiological appearances of invasive cribriform carcinoma of the breast. Clin Radiol 1994; 49: 693-695.
25. Page DL, Dixon JM, Anderson TJ et al. Invasive cribriform carcinoma of the breast. Histopathology 1983; 7: 525-536.
26. Venable JG, Schwartz AM, Silverberg SG. Infiltrating cribriform carcinoma of the breast: A distinctive clinicopathologic entity. Hum Pathol 1990; 21: 333-338.
27. Righi L, Sapino A, Marchiò C et al. Neuroendocrine differentiation in breast cancer: Established facts and unresolved problems. Semin Diagn Pathol 2010; 27: 69-76.
28. López-Bonet E, Alonso-Ruano M, Barraza G et al. Solid neuroendocrine breast carcinomas: Incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep 2008; 20: 1369-1374.
29. Sapino A, Papotti M, Righi L et al. Clinical significance of neuroendocrine carcinoma of the breast. Ann Oncol 2001; 12(suppl 2): S115-S117.
30. Ridolfi RL, Rosen PP, Port A et al. Medullary carcinoma of the breast: A clinicopathologic study with 10 year follow-up. Cancer 1977; 40: 1365-1385.
31. Liberman L, LaTrenta LR, Samli B et al. Overdiagnosis of medullary carcinoma: A mammographic-pathologiccorrelative study. Radiology 1996; 201: 443-446.
32. Karan B, Pourbagher A, Bolat FA. Unusual malignant breast lesions: Imaging-pathological correlations. Diagn Interv Radiol 2012; 18: 270-276.
33. Majid AS, de Paredes ES, Doherty RD et al. Missed breast carcinoma: Pitfalls and pearls. Radiographics 2003; 23: 881-895.
34. Vu-Nishino H, Tavassoli FA, Ahrens WA et al. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiat Oncol Biol Phys 2005; 62: 1040-1047.
35. Vincent-Salomon A, Gruel N, Lucchesi C et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007; 9: R24.
36. Work ME, Andrulis IL, John EM et al. Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry. Breast Cancer Res Treat 2012; 134: 1209-1220.
37. Vranic S, Bender R, Palazzo J et al. A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. Hum Pathol 2013; 44: 301-309.
38. Glazebrook KN, Reynolds C, Smith RL et al. Adenoid cystic carcinoma of the breast. AJR Am J Roentgenol 2010; 194: 1391-1396.
39. Arpino G, Clark GM, Mohsin S et al. Adenoid cystic carcinoma of the breast: Molecular markers, treatment, and clinical outcome. Cancer 2002; 94: 2119-2127.
40. Cadoo KA, McArdle O, O'Shea AM et al. Management of unusual histological types of breast cancer. The Oncologist2012; 17: 1135-1145.
41. Thompson K, Grabowski J, Saltzstein SL et al. Adenoid cystic breast carcinoma: Is axillary staging necessary in all cases? Results from the California Cancer Registry. Breast J 2011; 17: 485-489.
42. Ghabach B, Anderson WF, Curtis RE et al. Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): A population-based cohort study. Breast Cancer Res 2010; 12: R54.
43. Peintinger F, Leibl S, Reitsamer R et al. Primary acinic cell carcinoma of the breast: A case report with long-term follow-up and review of the literature. Histopathology 2004; 45: 645-648.
44. Tixier H, Picard A, Guiu S et al. Long-term recurrence of secretory breast carcinoma with metastatic sentinel lymph nodes. Arch Gynecol Obstet 2011; 283(suppl 1): 77-78.
45. Ozguroglu M, Tascilar K, Ilvan S et al. Secretory carcinoma of the breast: Case report and review of the literature. Oncology 2005; 68: 263-268.
46. Vieni S, Cabibi D, Cipolla C et al. Secretory breast carcinoma with metastatic sentinel lymph node. World J Surg Oncol 2006; 4: 88.
47. Mun SH, Ko EY, Han BK et al. Secretory carcinoma of the breast: Sonographic features. J Ultrasound Med 2008; 27: 947-954.
48. Tognon C, Knezevich SR, Huntsman D et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367-376.
49. Herz H, Cooke B, Goldstein D. Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: Case report and review of the literature. Ann Oncol 2000; 11: 1343-1347.
50. Zagorianakou P, Zagorianakou N, Stefanou D et al. The enigmatic nature of apocrine breast lesions. Virchows Arch 2006; 448: 525-531.
51. Rosen PP. Rosen's Breast Pathology. Philadelphia, PA: Lippincott Williams & Wilkins, 2001.
52. Japaze H, Emina J, Diaz C et al. "Pure" invasive apocrine carcinoma of the breast: A new clinicopathological entity? Breast 2005; 14: 3-10.
53. Vranic S, Tawfik O, Palazzo J et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 2010; 23: 644-653.
54. Dellapasqua S, Maisonneuve P, Viale G et al. Immunohistochemically defined subtypes and outcome of apocrine breast cancer. Clin Breast Cancer 2013; 13: 95-102.
55. MontagnaE, Maisonneuve P, Rotmensz N et al. Heterogeneity of triple-negative breast cancer: Histologic subtyping to inform the outcome. Clin Breast Cancer 2013; 13: 31-39.
56. Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol 1992; 23: 1167-1171.
57. Butler D, Rosa M. Pleomorphic lobular carcinoma of the breast: A morphologically and clinically distinct variant of lobular carcinoma. Arch Pathol Lab Med 2013; 137: 1688-1692.
58. Eusebi V, Magalhaes F, Azzopardi JG. Pleomorphic lobular carcinoma of the breast: An aggressive tumor showing apocrine differentiation. Hum Pathol 1992; 23: 655-662.
59. Jacobs M, Fan F, Tawfik O. Clinicopathologic and biomarker analysis of invasive pleomorphic lobular carcinoma as compared with invasive classic lobular carcinoma: An experience in our institution and review of the literature. Ann Diagn Pathol 2012; 16: 185-189.
60. Jung HN, Shin JH, Han BK et al. Are the imaging features of the pleomorphic variant of invasive lobular carcinoma different from classic ILC of the breast? Breast 2013; 22: 324-329.
61. Pettinato G, Manivel CJ, Panico L et al. Invasive micropapillary carcinoma of the breast: Clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol 2004; 121: 857-866.
62. Zekioglu O, Erhan Y, Ciris M et al. Invasive micropapillary carcinoma of the breast: High incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma. Histopathology 2004; 44: 18-23.
63. Walsh MM, Bleiweiss IJ. Invasivemicropapillary carcinoma of the breast: Eighty cases of an underrecognized entity. Hum Pathol 2001; 32: 583-589.
64. Günhan-Bilgen I, Zekioglu O, Ustün EE et al. Invasive micropapillary carcinoma of the breast: Clinical, mammographic, and sonographic findings with histopathologic correlation. AJR Am J Roentgenol 2002; 179: 927-931.
65. Chen L, Fan Y, Lang RG et al. Breast carcinoma with micropapillary features: Clinicopathologic study and long-term follow-up of 100 cases. Int J Surg Pathol 2008; 16: 155-163.
66. Pezzi CM, Patel-Parekh L, Cole K et al. Characteristics and treatment of metaplastic breast cancer: Analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 2007; 14: 166-173.
67. Jung SY, Kim HY, Nam BH et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 2010; 120: 627-637.
68. Al Sayed AD, El Weshi AN, Tulbah AM et al. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta Oncol 2006; 45: 188-195.
69. Günhan-Bilgen I, Memis A, Ustün EE et al. Metaplastic carcinoma of the breast: Clinical, mammographic, and sonographic findings with histopathologic correlation. AJR Am J Roentgenol 2002; 178: 1421-1425.
70. Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma: Rare types: Review of the literature. Ann Oncol 2009; 20: 1763-1770.
71. Hennessy BT, Krishnamurthy S, Giordano S et al. Squamous cell carcinoma of the breast. J Clin Oncol 2005; 23: 7827-7835.
72. Tse GM, Tan PH, Putti TC et al. Metaplastic carcinoma of the breast: A clinicopathological review. J Clin Pathol 2006; 59: 1079-1083.
73. Alkaied H, Harris K, Azab B et al. Primary neuroendocrine breast cancer, how much do we know so far? Med Oncol 2012; 29: 2613-2618.
74. Lacroix-Triki M, Suarez PH, MacKay A et al. Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol 2010; 222: 282-298.
75. Wetterskog D, Lopez-Garcia MA, Lambros MB et al. Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2012; 226: 84-96.
76. Kehr EL, Jorns JM, Ang D et al. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. Hum Pathol 2012; 43: 2207-2212.
77. Dieci MV, Lefebvre C, Scott V et al. Whole exome sequencing of rare aggressive breast cancer histologies reveal novel pathways for breast cancer progression. Paper presented at: 2013 San Antonio Breast Cancer Symposium, December 10-14, 2013; San Antonio, TX. Abstract 798.
78. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
79. Natrajan R, Wilkerson PM, Marchiò C et al. Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol 2014; 232: 553-565.
80. Vo T, Xing Y, Meric-Bernstam F et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg 2007; 194: 527-531.
81. NCCN Clinical Practice Guidelines in Oncology. NCCN Guidelines, Breast Cancer v1.2014. Available at http: //www. nccn. org/professionals/physician_gls/ pdf/breast. pdf. Accessed February 27, 2014.
82. Nagao T, Kinoshita T, Hojo T et al. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: The relationship between the outcome and the clinicopathological characteristics. Breast 2012; 21: 289-295.
83. Chen IC, Lin CH, Huang CS et al. Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat 2011; 130: 345-351.
84. Hennessy BT, Giordano S, Broglio K et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol 2006; 17: 605-613.
85. Brown-Glaberman U, Graham A, Stopeck A. A case of metaplastic carcinoma of the breast responsive to chemotherapy with ifosfamide and etoposide: Improved antitumor response by targeting sarcomatous features. Breast J 2010; 16: 663-665.
86. Hennessy BT, Gonzalez-Angulo A-M, StemkeHale K et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-tomesenchymal transition and stem cell characteristics. Cancer Res 2009; 69: 4116-4124.
87. Kimura F, Iwaya K, Kawaguchi T et al. Epidermal growth factor-dependent enhancement of invasiveness of squamous cell carcinoma of the breast. Cancer Sci 2010; 101: 1133-1140.